Ticagrelor Tablet
Product Images NDC 50268-826

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 50268-826). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (826 01)

Ticagrelor Tablets 90 mg oral tablet packaging label by AvPAK, showing a bulk package containing 100 tablets (10 x 10 unit-dose). The label includes storage instructions, a warning to keep out of reach of children, and manufacturing information for AvKARE and MSN Laboratories. The package is marked Rx only and features a barcode and NDC 50268-826-01.*

FDA Label Image

Tica-tabs-fig-01 (Tica Tabs Fig 01)

A cumulative incidence graph comparing the percentage of patients with events over 360 days from first study drug dose for Ticagrelor 90 mg and Clopidogrel. The X-axis shows days from first dose and the Y-axis shows cumulative percentage. The graph includes patient counts at risk at various time points and summary event data in a table inset.*

FDA Label Image

Tica-tabs-fig-02 (Tica Tabs Fig 02)

A bar chart showing the percentage of patients who had an event following CABG over several days, comparing two groups labeled T and C, with values displayed as paired black and striped bars for each day interval.*

FDA Label Image

Tica-tabs-fig-03 (Tica Tabs Fig 03)

A line graph showing cumulative percentage over months from randomization, comparing two groups labeled as Ticagrelor and Placebo. The x-axis represents months from randomization, with data points at intervals up to 54 months, while the y-axis shows cumulative percentage with values ranging up to approximately 4%. The graph includes a legend distinguishing Ticagrelor and Placebo with solid and dashed lines respectively.*

FDA Label Image

Tica-tabs-fig-04 (Tica Tabs Fig 04)

A line graph comparing cumulative outcomes over days from randomization between Ticagrelor 90 mg tablet and placebo groups. The x-axis shows time in days up to 34, and the y-axis shows cumulative proportions. Ticagrelor demonstrates higher cumulative values than placebo throughout the period.*

FDA Label Image

Tica-tabs-fig-05 (Tica Tabs Fig 05)

A pharmacokinetic curve comparing platelet reactivity inhibition (PRI) over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo. The graph displays PRI percentages tracked up to 8 hours post-dose, showing marked inhibition with Ticagrelor and lesser effects for Clopidogrel and Placebo.*

FDA Label Image

Tica-tabs-fig-06 (Tica Tabs Fig 06)

This image shows two line graphs depicting platelet aggregation inhibition (IPA %) over time for Ticagrelor, Clopidogrel, and Placebo. The main graph shows IPA % induced by 20μM ADP over a period of 10 days. The inset graph shows IPA % induced by 20μM ADP over a shorter time frame in hours. Ticagrelor demonstrates the highest inhibition, followed by Clopidogrel and Placebo.*

FDA Label Image

Tica-tabs-fig-07 (Tica Tabs Fig 07)

A chart presenting the mean effect and 90% confidence intervals for Ticagrelor and AR-C124910XX based on intrinsic factors including age, gender, ethnicity, renal impairment, end stage renal disease, and hepatic impairment. The chart compares pharmacokinetic parameters Cmax and AUC relative to reference values, with corresponding dosing recommendations indicating no dose adjustment required for all factors.*

FDA Label Image

Tica-tabs-fig-08 (Tica Tabs Fig 08)

A chart comparing the mean effect and 90% confidence intervals of interacting drugs on Ticagrelor and AR-C124910XX, illustrating changes relative to a reference for various CYP3A4 inhibitors, inducers, and other drugs. Recommendations for dose adjustments or concomitant use are listed alongside each interacting drug.*

FDA Label Image

Tica-tabs-fig-09 (Tica Tabs Fig 09)

A forest plot chart showing the interaction effects of various drugs when taken with different doses of Ticagrelor. It compares mean effects with 90% confidence intervals on variables Cmax, AUC, and PK, alongside dosing recommendations indicating whether dose adjustments are necessary.*

FDA Label Image

Tica-tabs-fig-10 (Tica Tabs Fig 10)

A cumulative percentage over time line graph comparing two groups labeled Ti 90 mg and Clopidogrel, showing cumulative event rates across 360 days from randomization. The graph includes a risk table with numbers of patients at risk at various time points and a legend with statistical data comparing event rates between groups.*

FDA Label Image

Tica-tabs-fig-11 (Tica Tabs Fig 11)

A forest plot chart comparing the treatment effects of Ticagrelor versus Clopidogrel across various patient characteristics and subgroups. The horizontal axis indicates hazard ratios, with Ticagrelor favored to the left and Clopidogrel to the right. Data points with confidence intervals are shown for overall treatment effect and multiple clinical and demographic categories such as geographic region, treatment approach, age, sex, diabetes history, and race.*

FDA Label Image

Tica-tabs-fig-12 (Tica Tabs Fig 12)

A forest plot chart comparing the hazard ratio (HR) with 95% confidence intervals for Ticagrelor versus Clopidogrel across different aspirin (ASA) dose subgroups in US and non-US regions. The horizontal axis represents the hazard ratio scale from 0.125 to 8, indicating whether Ticagrelor or Clopidogrel is favored. Data points for HR with confidence intervals are plotted for ASA doses greater than or equal to 300 mg, between 100 and 300 mg, and less than or equal to 100 mg in each region.*

FDA Label Image

Tica-tabs-fig-13 (Tica Tabs Fig 13)

A Kaplan-Meier cumulative percentage curve chart showing event rates over days from randomization for three groups: Ticagrelor 90 mg, Ticagrelor 60 mg, and Placebo. The x-axis represents days from randomization, and the y-axis shows cumulative percentage of patients with events. Data include number of patients at risk at various time points, hazard ratios, confidence intervals, and p-values for comparison between groups.*

FDA Label Image

Tica-tabs-fig-14 (Tica Tabs Fig 14)

A forest plot figure comparing the overall treatment effect of Ticagrelor 90 mg tablets versus placebo across various patient subgroups. The chart shows hazard ratios (HR) with 95% confidence intervals for factors like age, sex, region, BMI, history of MI, time from qualifying MI to randomization, and other clinical characteristics, illustrating relative efficacy between Ticagrelor and placebo groups.*

FDA Label Image

Tica-tabs-fig-15 (Tica Tabs Fig 15)

A Kaplan-Meier cumulative percentage graph depicting event rates over 54 months from randomization for Ticagrelor and placebo groups. The solid line represents Ticagrelor, and the dashed line represents placebo, showing cumulative event percentages on the Y-axis and months on the X-axis. Below the graph, the number at risk is shown for each time point for both groups.*

FDA Label Image

Tica-tabs-fig-16 (Tica Tabs Fig 16)

A forest plot chart depicting hazard ratios with 95% confidence intervals comparing Ticagrelor 90 mg tablets to placebo across various patient subgroups, including age, sex, race, smoking status, diabetes duration, and clinical history factors. The chart illustrates relative treatment effects for Ticagrelor versus placebo, with markers and horizontal lines representing confidence intervals for each subgroup analysis.*

FDA Label Image

Tica-tabs-fig-17 (Tica Tabs Fig 17)

A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg tablet and placebo over time in days from randomization. The graph shows cumulative percentage on the y-axis and days from randomization on the x-axis, with distinct curves for Ticagrelor and placebo groups.*

FDA Label Image

Tica-tabs-fig-18 (Tica Tabs Fig 18)

A forest plot displaying hazard ratios (HR) with 95% confidence intervals comparing outcomes between Ticagrelor and placebo groups across various patient characteristics such as age, sex, race, weight, BMI, geographic region, diagnosis, time from index event to randomization or loading dose, diabetes, hypertension, prior ischemic events, statin treatment, and smoking status. The plot visually shows relative treatment effects favoring Ticagrelor or placebo.*

FDA Label Image

Tica-tabs-structure (Tica Tabs Structure)

Chemical structure of ticagrelor, showing its molecular arrangement with labeled atoms and bonds as typically depicted for the active ingredient in this oral tablet formulation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.